Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zaleplon controlled release - SkyePharma/Somnus

Next Previous
X
Search
Drug Profile

Zaleplon controlled release - SkyePharma/Somnus

Alternative Names: SKP-1041

Latest Information Update: 09 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkyePharma AG
  • Developer Somnus Therapeutics
  • Class Acetamides; Hypnosedatives; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Sleep maintenance insomnia

Most Recent Events

  • 23 Apr 2012 Zaleplon controlled release - SkyePharma/Somnus is available for licensing as of 23 Apr 2012. www.somnusthera.com
  • 16 Jun 2011 Final efficacy data from a phase II trial in Sleep maintenance insomnia released by Somnus Therapeutics
  • 28 Feb 2011 Somnus Therapeutics completes a phase II trial in Sleep maintenance insomnia in USA (NCT00878553)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top